Targeting the Hepatic BMP-SMAD Pathway in Leptin Receptor Deficiency (LEPRD) (THOLD)

September 17, 2026 updated by: Flavia Prodam, Azienda Ospedaliero Universitaria Maggiore della Carita

Targeting the Hepatic BMP-SMAD Pathway in Leptin Receptor Deficiency (LEPRD): A New Strategy for Treating Severe Genetic Obesity or Leptin Deficiency

The goal of this observational study is to learn more about the role of TMPRSS6 in patients with leptin receptor deficiency (LEPRD) or genetic lipodystrophy associated with leptin deficiency. LEPRD is a rare genetic condition that causes severe obesity and excessive hunger, while genetic lipodystrophy is characterized by a loss of body fat and can be associated with severe metabolic problems.

The main questions it aims to answer are:

Is TMPRSS6 associated with metabolic and liver health in patients with LEPRD or genetic lipodystrophy? Are differences in TMPRSS6 levels or activity associated with blood sugar control, lipid levels, body fat, or liver health?

Participants will:

Provide a blood sample for the measurement of TMPRSS6 and other metabolic and molecular markers.

Have information from their clinical and laboratory assessments collected for the study.

This study may help researchers better understand the mechanisms underlying metabolic complications in LEPRD and genetic lipodystrophy and may contribute to the identification of new potential therapeutic targets in the future.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Leptin receptor deficiency (LEPRD) is an extremely rare autosomal recessive endocrine disorder characterized by severe early-onset obesity, hyperphagia, and metabolic abnormalities resulting from impaired leptin signaling. Genetic forms of lipodystrophy, including generalized and partial lipodystrophy, may also be associated with severe leptin deficiency and impaired leptin signaling, leading to abnormalities in glucose and lipid metabolism and ectopic fat accumulation, particularly in the liver.

Current therapeutic approaches do not fully address the metabolic complications associated with these rare disorders. In patients with LEPRD, setmelanotide, a selective melanocortin-4 receptor (MC4R) agonist, acts downstream of the leptin-melanocortin pathway and can substantially reduce hunger and body weight. However, the response to treatment may be limited in some patients, and metabolic and hepatic abnormalities may persist. Similarly, metreleptin replacement therapy used in selected forms of genetic lipodystrophy may not completely correct all metabolic and hepatic abnormalities. Therefore, identification of additional molecular pathways involved in the metabolic complications of these conditions is needed.

TMPRSS6 is a type II transmembrane serine protease predominantly expressed in hepatocytes. It negatively regulates hepatic BMP-SMAD signaling by cleaving hemojuvelin (HJV), a coreceptor of the BMP pathway, thereby contributing to the regulation of hepcidin production. Preclinical studies have shown that genetic inactivation or antisense oligonucleotide-mediated silencing of Tmprss6 in mice results in activation of the hepatic BMP-SMAD pathway and is associated with beneficial metabolic effects, including improved glucose metabolism, reduced adipose tissue accumulation, and attenuation of inflammation.

Preliminary studies in murine models have identified circulating liver-derived factors, including TMPRSS6-related molecular markers, that may be involved in the metabolic alterations associated with impaired leptin signaling. These findings suggest that TMPRSS6 and the hepatic BMP-SMAD pathway may play a role in the interaction between hepatic function and systemic glucose and lipid metabolism.

The present pilot observational study is designed to investigate whether molecular alterations identified in preclinical models are also detectable in humans with LEPRD or genetic lipodystrophy associated with leptin deficiency. Blood samples will be collected to measure circulating TMPRSS6 and other molecular or metabolic markers previously identified in preclinical studies as being regulated by or associated with TMPRSS6 activity.

The study will integrate these molecular findings with available clinical and biochemical characteristics of the participants. Particular attention will be given to markers of glucose and lipid metabolism and hepatic involvement, in order to explore potential associations between TMPRSS6-related markers and the metabolic phenotype of these rare disorders.

The study is intended to provide preliminary evidence regarding the relevance of the TMPRSS6-related pathway in humans. Identification of a specific circulating molecular signature associated with TMPRSS6 may improve understanding of the mechanisms underlying metabolic and hepatic complications in LEPRD and genetic lipodystrophy and provide a rationale for future translational studies investigating this pathway as a potential therapeutic target.

Study Type

Observational

Enrollment (Estimated)

35

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Italy
      • Novara, Italy, Italy, 28100
        • Recruiting
        • AOU Maggiore della Carità - SCDU Endocrinology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The study population will include pediatric and adult patients of both sexes with leptin receptor deficiency (LEPRD) or genetically determined leptin deficiency associated with generalized or partial lipodystrophy. Approximately 35 patients with genetic lipodystrophy and up to 10 patients with LEPRD will be enrolled. Participants may be untreated or receiving setmelanotide or metreleptin.

Description

Inclusion Criteria:

  • Male or female participants aged 0 to 99 years.
  • Diagnosis of leptin receptor deficiency (LEPRD) or genetically determined leptin deficiency associated with generalized or partial lipodystrophy.
  • Participants may be untreated or receiving treatment with setmelanotide or metreleptin.
  • Ability and willingness to provide written informed consent. For participants under the legal age, informed consent will be obtained from the parent(s) or legal guardian(s), together with assent from the minor when appropriate.

Exclusion Criteria:

  • Diagnosis of another form of genetic obesity.
  • Pregnancy or planned pregnancy during the study participation period.
  • Liver disease or hepatic impairment attributable to other causes, including excessive alcohol consumption.
  • Genetically determined dyslipidemia due to another cause.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Circulating Hepatokine Levels
Time Frame: At study enrollment

Measurement of circulating hepatokines, including TMPRSS6, in serum and plasma using immunoenzymatic assays such as ELISA or multiplex assays, and assessment of their association with clinical and biochemical parameters related to glucose metabolism, lipid metabolism, and liver health.

At study enrollment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 10, 2026

Primary Completion (Estimated)

September 1, 2028

Study Completion (Estimated)

September 1, 2029

Study Registration Dates

First Submitted

September 7, 2026

First Submitted That Met QC Criteria

September 17, 2026

First Posted (Actual)

September 22, 2026

Study Record Updates

Last Update Posted (Actual)

September 22, 2026

Last Update Submitted That Met QC Criteria

September 17, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • CE073/2026

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.